This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1990;39(6):613-4.

doi: 10.1007/BF00316110.

Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type

J W Meyer, B Woggon, P Baumann, U A Meyer

PMID: 2095351
DOI: 10.1007/BF00316110

Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type

J W Meyer et al. Eur J Clin Pharmacol. 1990.

. 1990;39(6):613-4.

doi: 10.1007/BF00316110.

Authors

J W Meyer, B Woggon, P Baumann, U A Meyer

PMID: 2095351
DOI: 10.1007/BF00316110

No abstract available

PubMed Disclaimer

Similar articles

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F. von Bahr C, et al. Clin Pharmacol Ther. 1991 Mar;49(3):234-40. doi: 10.1038/clpt.1991.22. Clin Pharmacol Ther. 1991. PMID: 2007317 Clinical Trial.
Debrisoquine oxidation phenotype during neuroleptic monotherapy.
Spina E, Martines C, Caputi AP, Cobaleda J, Piñas B, Carrillo JA, Benitez J. Spina E, et al. Eur J Clin Pharmacol. 1991;41(5):467-70. doi: 10.1007/BF00626371. Eur J Clin Pharmacol. 1991. PMID: 1684751
Debrisoquine oxidation in schizophrenic patients treated with neuroleptics.
Spina E, Buemi AL, Caputi AP, Benitez J, Cobaleda J, Garcia MA, Llerena A, Piña B. Spina E, et al. Pharmacol Res Commun. 1988 Dec;20(12):1103-4. doi: 10.1016/s0031-6989(88)80747-1. Pharmacol Res Commun. 1988. PMID: 2905478 No abstract available.
Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M. Eichelbaum M. Prog Clin Biol Res. 1986;214:157-67. Prog Clin Biol Res. 1986. PMID: 3523506 Review. No abstract available.
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS, Tucker GT, Woods HF. Lennard MS, et al. Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001. Clin Pharmacokinet. 1986. PMID: 2868819 Review.

See all similar articles

Cited by

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.
Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP. Spina E, et al. Eur J Clin Pharmacol. 1992;42(3):347-8. doi: 10.1007/BF00266363. Eur J Clin Pharmacol. 1992. PMID: 1349529 No abstract available.
Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.
Fang J, Gorrod JW. Fang J, et al. Cell Mol Neurobiol. 1999 Aug;19(4):491-510. doi: 10.1023/a:1006938908284. Cell Mol Neurobiol. 1999. PMID: 10379422 Free PMC article. Review.
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR. Shah RR. Drug Saf. 2004;27(3):145-72. doi: 10.2165/00002018-200427030-00001. Drug Saf. 2004. PMID: 14756578 Review.
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Dahl ML. Dahl ML. Clin Pharmacokinet. 2002;41(7):453-70. doi: 10.2165/00003088-200241070-00001. Clin Pharmacokinet. 2002. PMID: 12083975 Review.
Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A, Stout CD, Zhang Q, Johnson EF. Wang A, et al. J Biol Chem. 2015 Feb 20;290(8):5092-5104. doi: 10.1074/jbc.M114.627661. Epub 2015 Jan 1. J Biol Chem. 2015. PMID: 25555909 Free PMC article.

See all "Cited by" articles

References

1. Eur J Clin Pharmacol. 1979 Sep;16(3):183-7 - PubMed
1. Xenobiotica. 1986 May;16(5):449-64 - PubMed
1. Clin Pharmacol Ther. 1985 Dec;38(6):618-24 - PubMed
1. Nature. 1988 Feb 4;331(6155):442-6 - PubMed
1. Lancet. 1977 Sep 17;2(8038):584-6 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer